Feel Therapeutics, the Digital Precision Medicine company for
mental and behavioral health, today announces the recent granting
of US Patent No. 11,967,339 by the United States Patent and
Trademark Office, marking the company's achievement of its second
patent milestone in Emotion AI technology. Entitled "Method for
detecting and recognizing an emotional state of a user," this
patent represents a significant development for Feel Therapeutics,
extending the scope of its innovative and proprietary technology
previously established in US Patent No. 11,410,682.
SAN
FRANCISCO, May 16, 2024 /PRNewswire-PRWeb/ --
Leveraging AI to Detect Emotional Changes through Physiological
Data from Wearables
Feel Therapeutics Granted 2nd Patent for
Emotion AI Technology
San Francisco, CA, April 30, 2024 - Feel Therapeutics, the Digital
Precision Medicine company for mental and behavioral health, today
announces the recent granting of US Patent No. 11,967,339 by the
United States Patent and Trademark Office, marking the company's
achievement of its second patent milestone in Emotion AI
technology. Entitled "Method for detecting and recognizing an
emotional state of a user," this patent represents a significant
development for Feel Therapeutics, extending the scope of its
innovative and proprietary technology previously established in US
Patent No. 11,410,682.
Feel Therapeutics' AI technology passively and continuously
monitors physiological signals through a proprietary wearable
device, mobile phone sensors, voice, video, and the Feel
application to detect emotional changes. To ensure even more
precise measurement of the user's mood state, Feel's wearable
device incorporates several sensors, including a continuous
electrodermal activity (EDA) sensor, Photoplethysmography (PPG),
Skin Temperature, Inertial Measurements, as well as an
Environmental Temperature and Humidity Sensor. These enhancements
bolster the accuracy and reliability of emotion detection,
minimizing the impact of external factors on collected
physiological data.
This latest patent underscores Feel Therapeutics' unwavering
commitment to decoding mental health through advanced technology.
The Emotion Detection Technology developed by Feel Therapeutics
integrates cutting-edge machine learning and signal processing
algorithms and methods. These algorithms analyze a fusion of
multimodal data such as physiological as well as voice & video
data to develop emotion AI technology and identify patterns
corresponding to specific emotional changes, offering personalized
support and/or real-time therapeutic interventions.
Haris Tsirmpas, PhD, co-founder, and CTO of Feel Therapeutics,
emphasized the significance of the new patent, stating, "This
extension to our previous patent underscores Feel Therapeutics'
ongoing commitment to pushing the boundaries of innovation in
mental health AI technology. Our Emotion Detection Technology,
powered by advanced AI algorithms that we have meticulously
developed and refined, represents a pivotal tool for unraveling the
intricacies of human emotion and delivering tailored support to
individuals in need."
This patent exemplifies Feel's steadfast dedication to ushering
in the era of digital precision medicine in psychiatry,
neuroscience, and beyond. "Our patent further solidifies Feel
Therapeutics' position as a leader in digital precision medicine
for mental and behavioral health" stated George Eleftheriou, CEO and co-founder of Feel
Therapeutics. "By continuously refining and expanding our
proprietary technology, we aim to reinvent the way we diagnose,
monitor, and care for mental health through continuous and passive
monitoring."
Feel's patent for emotion detection through AI technology is a
cornerstone of the expansive patent portfolio and intellectual
property of the company, reflective of years of relentless
innovation and expertise. In tandem with their ongoing
advancements, including a robust portfolio focused on digital
biomarkers for mental conditions such as depression, anxiety, ADHD
as well as sleep and stress related conditions. Feel Therapeutics
is steadfast in its mission to further enhance personalized,
data-driven digital precision medicine for mental health.
About Feel Therapeutics:
Feel Therapeutics is a Digital Precision Medicine company
bringing continuous and passive monitoring to reinvent the way we
diagnose, manage, and care for mental health.
The company is backed by top-tier investors (e.g., Felicis,
Anthemis, SOSV, Satori, et al.) and partners with several top
Pharmaceutical companies and CROs to monitor patients 24/7/365 and
deliver precise support or interventions.
For more information about our work in mental health care, visit
www.feeltherapeutics.com.
Media Contact
Eri Christogianni, Feel Therapeutics, 30 6948952328,
eri@feeltherapeutics.com,
https://www.feeltherapeutics.com/
LinkedIn
View original
content:https://www.prweb.com/releases/feel-therapeutics-granted-2nd-patent-for-emotion-ai-technology-302147425.html
SOURCE Feel Therapeutics